ToolGen, Inc. Demonstrates Potential of CRISPR/cas9 Gene Editing to Overcome T-Cell Immunosuppression – GlobeNewswire (press release)
|
ToolGen, Inc. Demonstrates Potential of CRISPR/cas9 Gene Editing to Overcome T-Cell Immunosuppression
GlobeNewswire (press release) SEOUL, South Korea, Dec. 11, 2017 (GLOBE NEWSWIRE) — ToolGen, Inc. (KONEX, 199800), a biotechnology company specializing in genome editing, today announced data demonstrating that the Company's CRISPR/Cas9 gene editing platform can target and disrupt … |
